|
1
|
Louis DN, Perry A, Reifenberger G, von
Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD,
Kleihues P and Ellison DW: The 2016 World Health Organization
classification of tumors of the central nervous system: A summary.
Acta Neuropathol. 131:803–820. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Massimino M, Biassoni V, Gandola L, Garrè
ML, Gatta G, Giangaspero F, Poggi G and Rutkowski S: Childhood
medulloblastoma. Crit Rev Oncol Hematol. 105:35–51. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Warnke PC, Kopitzki K, Timmer J and
Ostertag CB: Capillary physiology of human medulloblastoma: Impact
on chemotherapy. Cancer. 107:2223–2227. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Palmer SL: Neurodevelopmental impacts on
children treatment for medulloblastoma: A review and proposed
conceptual model. Dev Dis Res Rev. 14:203–210. 2008. View Article : Google Scholar
|
|
5
|
Huang GH, Xu QF, Cui YH, Li N, Bian XW and
Lv SQ: Medulloblastoma stem cells: Promising targets in
medulloblastoma therapy. Cancer Sci. 107:583–589. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Evans SM, Judy KD, Dunphy I, Jenkins WT,
Hwang WT, Nelson PT, Lustig RA, Jenkins K, Magarelli DP, Hahn SM,
et al: Hypoxia is important in the biology and aggression of human
glial brain tumors. Clin Cancer Res. 10:8177–8184. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Michel G, Minet E, Ernest I, Roland I,
Durant F, Remacle J and Michiels C: A model for the complex between
the hypoxia-inducible factor-1 (HIF-1) and its consensus DNA
sequence. J Biomol Struct Dyn. 18:169–179. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hussein D, Estlin EJ, Dive C and Makin GW:
Chronic hypoxia promotes hypoxia-inducible factor-1alpha-dependent
resistance to etoposide and vincristine in neuroblastoma cells. Mol
Cancer Ther. 5:2241–2250. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Liu L, Ning X, Sun L, Zhang H, Shi Y, Guo
C, Han S, Liu J, Sun S, Han Z, et al: Hypoxia-inducible factor-1
alpha contributes to hypoxia-induced chemoresistance in gastric
cancer. Cancer Sci. 99:121–128. 2008.PubMed/NCBI
|
|
10
|
Rho JK, Choi YJ, Lee JK, Ryoo BY, Na II,
Yang SH, Kim CH, Yoo YD and Lee JC: Gefitinib circumvents
hypoxia-induced drug resistance by the modulation of HIF-1alpha.
Oncol Rep. 21:801–807. 2009.PubMed/NCBI
|
|
11
|
Doublier S, Belisario D, Polimeni M,
Annaratone L, Riganti C, Allia E, Ghigo D, Bosia A and Sapino A:
HIF-1 activation induces doxorubicin resistance in MCF7 3-D
spheroids via P-glycoprotein expression: A potential model of the
chemoresistance of invasive micropapillary carcinoma of the breast.
BMC Cancer. 12:42012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Roncuzzi L, Pancotti F and Baldini N:
Involvement of HIF-1α activation in the doxorubicin resistance of
human osteosarcoma cells. Oncol Rep. 32:389–394. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Phillips RM: Targeting the hypoxic
fraction of tumours using hypoxia-activated prodrugs. Cancer Chemo
Pharmacol. 77:441–457. 2016. View Article : Google Scholar
|
|
14
|
Roy P, Yu L, Crespi C and Waxman D:
Development of a substrate-activity based approach to identify the
major human liver P-450 catalysts of cyclophosphamide and
ifosfamide activation based on cDNA-expressed activities and liver
microsomal P-450 profiles. Drug Metab Dispos. 27:655–666.
1999.PubMed/NCBI
|
|
15
|
Dhaini HR, Thomas DG, Giordano TJ, Johnson
TD, Biermann JS, Leu K, Hollenberg PF and Baker LH: Cytochrome P450
CYP3A4/5 expression as a biomarker of outcome in osteosarcoma. J
Clin Oncol. 21:2481–2485. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Murray GI, Patimalla S, Stewart KN, Miller
ID and Heys SD: Profiling the expression of cytochrome P450 in
breast cancer. Histopathology. 57:202–211. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chen TC, Sakaki T, Yamamoto K and Kittaka
A: The roles of cytochrome P450 enzymes in prostate cancer
development and treatment. Anticancer Res. 32:291–298.
2012.PubMed/NCBI
|
|
18
|
Qixing M, Juqing X, Yajing W, Gaochao D,
Wenjie X, Run S, Anpeng W, Lin X, Feng J and Jun W: The expression
levels of CYP3A4 and CYP3A5 serve as potential prognostic
biomarkers in lung adenocarcinoma. Tumour Biol.
39:10104283176983402017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
McFadyen MC, Melvin WT and Murray GI:
Cytochrome P450 enzymes: Novel options for cancer therapeutics. Mol
Cancer Ther. 3:363–371. 2004.PubMed/NCBI
|
|
20
|
Rodriguez-Antona C and Ingelman-Sundberg
M: Cytochrome P450 pharmacogenetics and cancer. Oncogene.
25:1679–1691. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Legendre C, Hori T, Loyer P, Aninat C,
Ishida S, Glaise D, Lucas-Clerc C, Boudjema K, Guguen-Guillouzo C,
Corlu A and Morel F: Drug-metabolising enzymes are down-regulated
by hypoxia in differentiated human hepatoma HepaRG cells:
HIF-1alpha involvement in CYP3A4 repression. Eur J Cancer.
45:2882–2892. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Niemira M, Dastych J and Mazerska Z:
Pregnane X receptor dependent up-regulation of CYP2C9 and CYP3A4 in
tumor cells by antitumor acridine agents, C-1748 and C-1305,
selectively diminished under hipoxia. Biochem Pharmacol.
86:231–241. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
McErlane V, Yakkundi A, McCarthy HO,
Hughes CM, Patterson LH, Hirst DG, Robson T and McKeown SR: A
cytochrome P450 2B6 meditated gene therapy strategy to enhance the
effects of radiation or cyclophosphamide when combined with the
bioreductive drug AQ4N. J Gene Med. 7:851–859. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Fradette C and Souich P: Effect of hypoxia
on cytochrome P450 activity and expression. Curr Drug Metab.
5:257–271. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Michaelis UR, Fisslthaler B,
Barbosa-Sicard E, Falck JR, Fleming I and Busse R: Cytochrome P450
epoxygenases 2C8 and 2C9 are implicated in hypoxia-induced
endothelial cell migration and angiogenesis. J Cell Sci.
118:5489–5498. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Fradette C, Batonga J, Teng S,
Piquette-Miller M and du Souich P: Animal models of acute moderate
hypoxia are associated with a down-regulation of CYP1A1, 1A2, 2B4,
2C5, and 2C16 and up-regulation of CYP3A6 and P-glycoprotein in
liver. Drug Metab Dispos. 35:765–771. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Jewell UR, Kvietikova I, Scheid A, Bauer
C, Wenger RH and Gassmann M: Induction of HIF-1alpha in response to
hypoxia is instantaneous. FASEB J. 15:1312–1314. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Box AH and Demetrick DJ: Cell cycle kinase
inhibitor expression and hypoxia-induced cell cycle arrest in human
cancer cell lines. Carcinogenesis. 25:2325–2335. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Longley DB, Allen WL, McDermott U, Wilson
TR, Latif T, Boyer J, Lynch M and Johnston PG: The roles of
thymidylate synthase and p53 in regulating Fas-mediated apoptosis
in response to antimetabolites. Clin Cancer Res. 10:3562–3571.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chiche J, Brahimi-Horn MC and Pouysségur
J: Tumour hypoxia induces a metabolic shift causing acidosis: A
common feature in cancer. J Cell Mol Med. 14:771–794. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Swift LH and Golsteyn RM: Genotoxic
anti-cancer agents and their relationship to DNA damage, mitosis,
and checkpoint adaptation in proliferating cancer cells. Int J Mol
Sci. 15:3403–3431. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Huang Z, Roy P and Waxman DJ: Role of
human liver microsomal CYP3A4 and CYP2B6 in catalyzing
N-dechloroethylation of cyclophosphamide and ifosfamide. Biochem
Pharmacol. 59:961–972. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
O'Connor PM, Wassermann K, Sarang M,
Magrath I, Bohr VA and Kohn KW: Relationship between DNA
cross-links, cell cycle, and apoptosis in Burkitt's lymphoma cell
lines differing in sensitivity to nitrogen mustard. Cancer Res.
51:6550–6557. 1991.PubMed/NCBI
|
|
34
|
Shah MA and Schwartz GK: Cell
cycle-mediated drug resistance: An emerging concept in cancer
therapy. Clin Cancer Res. 7:2168–2181. 2001.PubMed/NCBI
|
|
35
|
Sun C, Wang G, Wrighton KH, Lin H,
Songyang Z, Feng XH and Lin X: Regulation of p27kip1
phosphorylation and G1 cell cycle progression by protein
phosphatase PPM1G. Am J Cancer Res. 6:2207–2220. 2016.PubMed/NCBI
|
|
36
|
Mabjeesh NJ, Escuin D, LaVallee TM,
Pribluda VS, Swartz GM, Johnson MS, Willard MT, Zhong H, Simons JW
and Giannakakou P: 2ME2 inhibits tumor growth and angiogenesis by
disrupting microtubules and dysregulating HIF. Cancer Cell.
3:363–75. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kaluz S, Kaluzová M, Liao SY, Lerman M and
Stanbridge EJ: Transcriptional control of the tumor- and
hypoxia-marker carbonic anhydrase 9: A one transcription factor
(HIF-1) show? Biochim Biophys Acta. 1795:162–172. 2009.PubMed/NCBI
|
|
38
|
Nordfors K, Haapasalo J, Korja M, Niemelä
A, Laine J, Parkkila AK, Pastorekova S, Pastorek J, Waheed A, Sly
WS, et al: The tumour-associated carbonic anhydrases CA II, CA IX
and CA XII in a group of medulloblastomas and supratentorial
primitive neuroectodermal tumours: An association of CA IX with
poor prognosis. BMC Cancer. 10:1482010. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Svastová E, Zilka N, Zat'ovicová M,
Gibadulinová A, Ciampor F, Pastorek J and Pastoreková S: Carbonic
anhydrase IX reduces E-cadherin-mediated adhesion of MDCK cells via
interaction with beta-catenin. Exp Cell Res. 290:332–345. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wykoff CC, Beasley NJ, Watson PH, Turner
KJ, Pastorek J, Sibtain A, Wilson GD, Turley H, Talks KL, Maxwell
PH, et al: Hypoxia-inducible expression of tumor-associated
carbonic anhydrases. Cancer Res. 60:7075–7083. 2000.PubMed/NCBI
|
|
41
|
Sowa T, Menju T, Chen-Yoshikawa TF,
Takahashi K, Nishikawa S, Nakanishi T, Shikuma K, Motoyama H,
Hijiya K, Aoyama A, et al: Hypoxia-inducible factor 1 promotes
chemoresistance of lung cancer by inducing carbonic anhydrase IX
expression. Cancer Med. 6:288–297. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Liu J, Wang Q, Wu DC, Wang XW, Sun Y, Chen
XY, Zhang KL and Li H: Differential regulation of CYP1A1 and CYP1B1
expression in resveratrol-treated human medulloblastoma cells.
Neurosci Lett. 363:257–261. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Schmidt R, Baumann F, Knüpfer H,
Brauckhoff M, Horn LC, Schönfelder M, Köhler U and Preiss R: CY
P3A4 CY P2C9 and CYP2B6 expression and ifosfamide turnover in
breast cancer tissue microsomes. Br J Cancer. 90:911–916. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Miyoshi Y, Taguchi T, Kim SJ, Tamaki Y and
Noguchi S: Prediction of response to docetaxel by
immunohistochemical analysis of CYP3A4 expression in human breast
cancers. Breast Cancer. 12:11–15. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Rodríguez-Antona C, Leskelä S, Zajac M,
Cuadros M, Alvés J, Moneo MV, Martín C, Cigudosa JC, Carnero A,
Robledo M, et al: Expression of CYP3A4 as a predictor of response
to chemotherapy in peripheral T-cell lymphomas. Blood.
110:3345–3351. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Zhu Z, Mu Y, Qi C, Wang J, Xi G, Guo J, Mi
R and Zhao F: CYP1B1 enhances the resistance of epithelial ovarian
cancer cells to paclitaxel in vivo and in vitro. Int
J Mol Med. 35:340–348. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Yoshida GJ: Metabolic reprogramming: The
emerging concept and associated therapeutic strategies. J Exp Clin
Cancer Res. 34:1112015. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Donovan L, Welford SM, Haaga J, LaManna J
and Strohl KP: Hypoxia-implications for pharmaceutical
developments. Sleep Breath. 14:291–298. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Erler JT, Cawthorne CJ, Williams KJ,
Koritzinsky M, Wouters BG, Wilson C, Miller C, Demonacos C,
Stratford IJ and Dive C: Hypoxia-mediated down-regulation of Bid
and Bax in tumors occurs via hypoxia-inducible factor 1-dependent
and -independent mechanisms and contributes to drug resistance. Mol
Cell Biol. 24:2875–2889. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Cui XY, Skretting G, Tinholt M, Stavik B,
Dahm AEA, Sahlberg KK, Kanse S, Iversen N and Sandset PM: A novel
hypoxia response element regulates oxygen-related repression of
tissue factor pathway inhibitor in the breast cancer cell line
MCF-7. Thromb Res. 157:111–116. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Li D, Du Y, Yuan X, Han X, Dong Z, Chen X,
Wu H, Zhang J, Xu L, Han C, et al: Hepatic hypoxia-inducible
factors inhibit PPARα expression to exacerbate acetaminophen
induced oxidative stress and hepatotoxicity. Free Radic Biol Med.
110:102–116. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Padró M, Louie RJ, Lananna BV, Krieg AJ,
Timmerman LA and Chan DA: Genome-independent hypoxic repression of
estrogen receptor alpha in breast cancer cells. BMC Cancer.
17:2032017. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Fradette C, Bleau AM, Pichette V, Chauret
N and Du Souich P: Hypoxia-induced down-regulation of CYP1A1/1A2
and up-regulation of CYP3A6 involves serum mediators. Br J
Pharmacol. 137:881–891. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Nishida CR, Lee M and de Montellano PR:
Efficient hypoxic activation of the anticancer agent AQ4N by CYP2S1
and CYP2W1. Mol Pharmacol. 78:497–502. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Soncini M, Corna G, Moresco M, Coltella N,
Restuccia U, Maggioni D, Raccosta L, Lin CY, Invernizzi F,
Crocchiolo R, et al: 24-Hydroxycholesterol participates in
pancreatic neuroendocrine tumor development. Proc Natl Acad Sci
USA. 113:E6219–E6227. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Anderson KM, Guinan P and Rubenstein M:
The effect of normoxia and hypoxia on a prostate (PC-3) CD44/CD41
cell side fraction. Anticancer Res. 31:487–494. 2011.PubMed/NCBI
|
|
57
|
Murono K, Tsuno NH, Kawai K, Sasaki K,
Hongo K, Kaneko M, Hiyoshi M, Tada N, Nirei T, Sunami E, et al:
SN-38 overcomes chemoresistance of colorectal cancer cells induced
by hypoxia, through HIF1alpha. Anticancer Res. 32:865–872.
2012.PubMed/NCBI
|
|
58
|
Richards R, Jenkinson MD, Haylock BJ and
See V: Cell cycle progression in glioblastoma cells is unaffected
by pathophysiological levels of hypoxia. Peer J. 4:e17552016.
View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Harrison MR, Hahn NM, Pili R, Oh WK,
Hammers H, Sweeney C, Kim K, Perlman S, Arnott J, Sidor C, et al: A
phase II study of 2-methoxyestradiol (2ME2) NanoCrystal®
dispersion (NCD) in patients with taxane-refractory, metastatic
castrate-resistant prostate cancer (CRPC). Invest New Drugs.
29:1465–1474. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Kulke MH, Chan JA, Meyerhardt JA, Zhu AX,
Abrams TA, Blaszkowsky LS, Regan E, Sidor C and Fuchs CS: A
prospective phase II study of 2-methoxyestradiol administered in
combination with bevacizumab in patients with metastatic carcinoid
tumors. Cancer Chemother Pharmacol. 68:293–300. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Ricker JL, Chen Z, Yang XP, Pribluda VS,
Swartz GM and Van Waes C: 2-methoxyestradiol inhibits
hypoxia-inducible factor 1alpha, tumor growth, and angiogenesis and
augments paclitaxel efficacy in head and neck squamous cell
carcinoma. Clin Cancer Res. 10:8665–8673. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Ma L, Li G, Zhu H, Dong X, Zhao D, Jiang
X, Li J, Qiao H, Ni S and Sun X: 2-methoxyestradiol synergizes with
sorafenib to suppress hepatocellular carcinoma by simultaneously
dysregulating hypoxia-inducible factor-1 and −2. Cancer Lett.
355:96–105. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Moon JY and Gwak HS: Role of the nuclear
pregnane X receptor in drug metabolism and the clinical response.
Receptors Clin Investig. 2:e9962015.
|
|
64
|
Handschin C and Meyer UA: Induction of
drug metabolism: The role of nuclear receptors. Pharmacol Rev.
55:649–673. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Plant N: The human cytochrome P450
sub-family: Transcriptional regulation, inter-individual variation
and interaction networks. Biochim Biophys Acta. 1770:478–488. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Yu AM, Tian Y, Tu MJ, Ho PY and Jilek JL:
MicroRNA pharmacoepigenetics: Posttranscriptional regulation
mechanisms behind variable drug disposition and strategy to develop
more effective therapy. Drug Metab Dispos. 44:308–319. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Adesina AM, Dunn ST, Moore WE and
Nalbantoglu J: Expression of p27kip1 and p53 in medulloblastoma:
Relationship with cell proliferation and survival. Pathol Res
Pract. 196:243–250. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Batsi C, Markopoulou S, Kontargiris E,
Charalambous C, Thomas C, Christoforidis S, Kanavaros P,
Constantinou AI, Marcu KB and Kolettas E: Bcl-2 blocks
2-methoxyestradiol induced leukemia cell apoptosis by a
p27Kip1-dependent G1/S cell cycle arrest in conjunction
with NF-κB activation. Biochem Pharmacol. 78:33–44. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Maran A, Shogren KL, Benedikt M, Sarkar G,
Turner RT and Yaszemski MJ: 2-methoxyestradiol-induced cell death
in osteosarcoma cells is preceded by cell cycle arrest. J Cell
Biochem. 104:1937–1945. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Alkarain A and Slingerland J: Deregulation
of p27 by oncogenic signaling and its prognostic significance in
breast cancer. Breast Cancer Res. 6:13–21. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Kumar AP, Garcia GE, Orsborn J, Levin VA
and Slaga TJ: 2-methoxyestradiol interferes with NF kappa B
transcriptional activity in primitive neuroectodermal brain tumors:
Implications for management. Carcinogenesis. 24:209–216. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Bruce JY, Eickhoff J, Pili R, Logan T,
Carducci M, Arnott J, Treston A, Wilding G and Liu G: A phase II
study of 2-methoxyestradiol nanocrystal colloidal dispersion alone
and in combination with sunitinib malate in patients with
metastatic renal cell carcinoma progressing on sunitinib malate.
Invest New Drugs. 30:794–802. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Gorska M, Kuban-Jankowska A, Zmijewski MA,
Gorzynik M, Szkatula M and Wozniak M: Neuronal nitric oxide
synthase induction in the antitumorigenic and neurotoxic effects of
2-methoxyestradiol. Molecules. 19:13267–13281. 2014. View Article : Google Scholar : PubMed/NCBI
|
